Abstract:Background: BRCA germline pathogenic variants represent the most common inherited mechanism predisposing individuals to breast cancer, while germline pathogenic variants in one of the mismatch repair (MMR) genes represent the most common colon cancer-predisposing inherited syndrome, known as the Lynch syndrome (LS). Individuals who harbor pathogenic germline variants for both syndromes are extremely rare. Germline testing is now done routinely for patients with breast cancer and MMR testing is recommended for nearly all patients diagnosed with colon or rectal cancer (Benson et al in NCCN clinical practice guidelines in oncology (NCCN guidelines) colon cancer (Version 4.2019-November 8, 2019). www.NCCN.org, Gradishar et al in NCCN clinical practice guidelines in oncology (NCCN guidelines) breast cancer (Version 3.2019-September 6, 2019).www.NCCN.org). We report a patient with germline mutations in both BRCA2 and the MMR gene MLH1 who developed breast cancer. The breast cancer showed loss of heterozygosity (LOH) in BRCA2 (the molecular hallmark of cancers related to inheritance of a BRCA alteration) and was also deficient in mismatch repair gene protein expression (dMMR), the hallmark of LS-related cancers. We discuss the possible mechanisms of transformation that would explain the finding that the tumor showed both BRCA2 LOH and was dMMR, each of which would generally be considered a gatekeeper event for transformation of normal cells to malignancy. Results: This report describes a patient with molecularly diagnosed breast and ovarian cancer syndrome (BRCA2) and LS. Next generation sequencing (NGS) and immunohistochemical (IHC) testing demonstrated her breast cancer to show BRCA2 LOH and to be dMMR. Conclusion: The patient presented represents the first reported case where both next generation sequencing (NGS) for BRCA LOH and MMR IHC testing of her breast cancer were performed and underscores the importance of using NGS including the reported mutational allelic frequency (MAF) and IHC use to predict the likely responsiveness to the recently approved PARP inhibitors and checkpoint inhibitor therapies (Robson et al in N Engl J Med 377:523-533, 2017, Lemery et al in 377(15):1409-1412, https://doi.org/10.1056/NEJMp1709968, 2017), key because the gatekeeper transforming event for tumors related to inherited cancer syndromes is loss of normal tumor suppressor gene (TSG) protein expression.

Surviving without BRCA2: MLH1 gets R-looped in to curtail genomic instability

Mismatch repair protein MLH1 suppresses replicative stress in BRCA2-deficient breast tumors

Abstract LB410: Contrasting roles of different mismatch repair proteins in basal like breast cancer

The implications of BRCA loss of heterozygosity (LOH) and deficient mismatch repair gene (dMMR) expression in the breast cancer of a patient with both inherited breast and ovarian cancer syndrome (BRCA2) and Lynch syndrome (MLH1)

53BP1 Loss Rescues Embryonic Lethality but Not Genomic Instability of BRCA1 Total Knockout Mice

Abstract 3019: Dissecting in vivo functions of R-Loops in Brca1 -associated DNA replication stress and mammary tumorigenesis

Abstract IA014: BRCA2 promotes genomic integrity and therapy resistance primarily through its role in homology-directed repair

BRCA2 associates with MCM10 to suppress PRIMPOL-mediated repriming and single-stranded gap formation after DNA damage

R-loop functions in Brca1-associated mammary tumorigenesis

The association between MLH1 -93 G>A polymorphism of DNA mismatch repair and cancer susceptibility: A meta-analysis

Deficiency of Human BRCA2 Leads to Impaired Homologous Recombination but Maintains Normal Nonhomologous End Joining

Mlh1 Mediates Tissue-Specific Regulation of Mitotic Recombination

BRCA1 and homologous recombination: implications from mouse embryonic development

Abstract A015: Mutations in mismatch repair genes that alter subcellular localization of the protein predict resistance to standard therapy but response to cell cycle inhibitors

MLH1 Deficiency-Triggered DNA Hyperexcision by Exonuclease 1 Activates the cGAS-STING Pathway

Distinct roles of the two BRCA2 DNA binding domains in DNA damage repair and replication fork preservation

"Bridging the DNA divide": Understanding the interplay between replication- gaps and homologous recombination proteins RAD51 and BRCA1/2

MutLα suppresses error-prone DNA mismatch repair and preferentially protects noncoding DNA from mutations

Direct Association of Bloom'S Syndrome Gene Product with the Human Mismatch Repair Protein Mlh1

The BRCA2-MEILB2-BRME1 complex governs meiotic recombination and impairs the mitotic BRCA2-RAD51 function in cancer cells

Human MLH1 suppresses the insertion of telomeric sequences at intra-chromosomal sites in telomerase-expressing cells